VTYX - Ventyx says lead asset well tolerated in a Phase 1 trial of healthy adults

Announcing initial data from a Phase 1 trial, the clinical-stage biopharma Ventyx Biosciences ( NASDAQ: VTYX ) said on Monday that its lead candidate VTX958 was well tolerated by 96 healthy adult volunteers who took part in the study.

The two-part, randomized study consisted of two portions in which seven cohorts and five cohorts were part of the trial's single ascending dose and multiple ascending dose sections, respectively.

According to the company, the study drug was well tolerated across all cohorts with no discontinuations due to adverse events. There were no drug-related serious adverse events or dose-limiting toxicities. All treatment-related adverse events were categorized as mild.

Additionally, the company said that VTX958, an allosteric TYK2 inhibitor, led to a dose-dependent increase in exposure through all cohorts in both SAD and the MAD portions.

VTX958 demonstrated a strong dose-dependent pharmacodynamic (PD) activity in the MAD portion of the trial, confirming its effect on TYK2-mediated pathways and suggesting in vivo evidence of target engagement.

The company plans to advance the candidate into several Phase 2 trials, targeting conditions such as psoriasis, Crohn's disease, and psoriatic arthritis in Q4 2022.

In May, Credit Suisse initiated the coverage on Ventyx ( VTYX ) with an Outperform recommendation citing the best-in-class potential of VTX958.

For further details see: